Precigen Inc (PGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precigen Inc (PGEN) has a cash flow conversion efficiency ratio of -1.122x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.46 Million) by net assets ($20.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Precigen Inc to measure how many days the company can operate on defensive assets alone.
Precigen Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Precigen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Precigen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precigen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Crun Co Ltd
SHE:002272
|
-0.006x |
|
Taiwan Fertilizer Co Ltd
TW:1722
|
0.004x |
|
Qisda Corp
TW:2352
|
-0.072x |
|
Hotel Shilla
KO:008770
|
-0.137x |
|
BGF Retail Co Ltd
KO:282330
|
0.268x |
|
Tetra Technologies Inc
NYSE:TTI
|
-0.042x |
|
Vietnam Export Import Commercial Joint Stock Bank
VN:EIB
|
0.296x |
|
C3 Ai Inc
NYSE:AI
|
-0.062x |
Annual Cash Flow Conversion Efficiency for Precigen Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Precigen Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Precigen Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.91 Million | $-87.83 Million | -4.200x | -137.28% |
| 2024-12-31 | $38.51 Million | $-68.17 Million | -1.770x | -213.40% |
| 2023-12-31 | $118.50 Million | $-66.93 Million | -0.565x | -9.64% |
| 2022-12-31 | $126.26 Million | $-65.05 Million | -0.515x | +0.84% |
| 2021-12-31 | $107.35 Million | $-55.77 Million | -0.520x | +54.69% |
| 2020-12-31 | $67.17 Million | $-77.02 Million | -1.147x | -6.75% |
| 2019-12-31 | $71.71 Million | $-77.02 Million | -1.074x | -227.40% |
| 2018-12-31 | $378.72 Million | $-124.24 Million | -0.328x | -72.17% |
| 2017-12-31 | $546.54 Million | $-104.14 Million | -0.191x | -93.77% |
| 2016-12-31 | $569.25 Million | $-55.98 Million | -0.098x | -294.32% |
| 2015-12-31 | $704.89 Million | $35.67 Million | 0.051x | +204.30% |
| 2014-12-31 | $409.29 Million | $-19.86 Million | -0.049x | +65.53% |
| 2013-12-31 | $381.34 Million | $-53.68 Million | -0.141x | -173.57% |
| 2012-12-31 | $-321.55 Million | $-61.53 Million | 0.191x | -48.22% |
| 2011-12-31 | $-221.26 Million | $-81.76 Million | 0.370x | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more